HANXBIO-B spends HKD 0.99 million to repurchase 31,200 H shares; outstanding shares (ex-treasury) trimmed to 135.94 million

Bulletin Express04-22 20:23

Hanx Biopharmaceuticals (Wuhan) Co., Ltd. (HANXBIO-B) disclosed that on 22 April 2026 it bought back 31,200 H shares on the Hong Kong Stock Exchange. The transaction was executed within a price range of HKD 31.18 to HKD 31.98 per share, translating into a volume-weighted average price of HKD 31.68 and an aggregate consideration of HKD 0.99 million.

Following the repurchase, the company’s issued shares excluding treasury shares fell by 0.0229% to 135.94 million. Treasury shares increased from 246,000 to 277,200, while total issued shares remained unchanged at 136.22 million because the repurchased shares are being held in treasury and have not been cancelled.

The buy-back was made under the general mandate approved on 12 February 2026, which authorises the company to repurchase up to 13.62 million shares. Including this transaction, cumulative repurchases under the mandate amount to 277,200 shares, equivalent to 0.2035% of the issued share base on the mandate date. Under Listing Rule 10.06, the company is restricted from issuing new shares or disposing of treasury shares until 22 May 2026.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1176038362?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-04-22 20:23","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1176038362","market":"hk","top_or_hot":-1,"title":"HANXBIO-B spends HKD 0.99 million to repurchase 31,200 H shares; outstanding shares (ex-treasury) trimmed to 135.94 million","media":"Bulletin Express","content":"<p>Hanx Biopharmaceuticals (Wuhan) Co., Ltd. (HANXBIO-B) disclosed that on 22 April 2026 it bought back 31,200 H shares on the Hong Kong Stock Exchange. The transaction was executed within a price range of HKD 31.18 to HKD 31.98 per share, translating into a volume-weighted average price of HKD 31.68 and an aggregate consideration of HKD 0.99 million.</p>\n<p>Following the repurchase, the company’s issued shares excluding treasury shares fell by 0.0229% to 135.94 million. Treasury shares increased from 246,000 to 277,200, while total issued shares remained unchanged at 136.22 million because the repurchased shares are being held in treasury and have not been cancelled.</p>\n<p>The buy-back was made under the general mandate approved on 12 February 2026, which authorises the company to repurchase up to 13.62 million shares. Including this transaction, cumulative repurchases under the mandate amount to 277,200 shares, equivalent to 0.2035% of the issued share base on the mandate date. Under Listing Rule 10.06, the company is restricted from issuing new shares or disposing of treasury shares until 22 May 2026.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>HANXBIO-B spends HKD 0.99 million to repurchase 31,200 H shares; outstanding shares (ex-treasury) trimmed to 135.94 million</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHANXBIO-B spends HKD 0.99 million to repurchase 31,200 H shares; outstanding shares (ex-treasury) trimmed to 135.94 million\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2026-04-22 20:23</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Hanx Biopharmaceuticals (Wuhan) Co., Ltd. (HANXBIO-B) disclosed that on 22 April 2026 it bought back 31,200 H shares on the Hong Kong Stock Exchange. The transaction was executed within a price range of HKD 31.18 to HKD 31.98 per share, translating into a volume-weighted average price of HKD 31.68 and an aggregate consideration of HKD 0.99 million.</p>\n<p>Following the repurchase, the company’s issued shares excluding treasury shares fell by 0.0229% to 135.94 million. Treasury shares increased from 246,000 to 277,200, while total issued shares remained unchanged at 136.22 million because the repurchased shares are being held in treasury and have not been cancelled.</p>\n<p>The buy-back was made under the general mandate approved on 12 February 2026, which authorises the company to repurchase up to 13.62 million shares. Including this transaction, cumulative repurchases under the mandate amount to 277,200 shares, equivalent to 0.2035% of the issued share base on the mandate date. Under Listing Rule 10.06, the company is restricted from issuing new shares or disposing of treasury shares until 22 May 2026.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"03378","symbol_name":"翰思艾泰-B","start_time":0,"source_url":"","article_id":"1176038362","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1176038362","pubTimestamp":1776860601,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"Hanx Biopharmaceuticals (Wuhan) Co., Ltd. (HANXBIO-B) disclosed that on 22 April 2026 it bought back 31,200 H shares on the Hong Kong Stock Exchange. The transaction was executed within a price range...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"03378":"翰思艾泰-B"},"translate_title":"HANXBIO-B斥资0.99万港元回购3.12万股H股；流通股（不含库存股）削减至1.3594亿股","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"03378":1},"content_text":"Hanx Biopharmaceuticals (Wuhan) Co., Ltd. (HANXBIO-B) disclosed that on 22 April 2026 it bought back 31,200 H shares on the Hong Kong Stock Exchange. The transaction was executed within a price range of HKD 31.18 to HKD 31.98 per share, translating into a volume-weighted average price of HKD 31.68 and an aggregate consideration of HKD 0.99 million.\nFollowing the repurchase, the company’s issued shares excluding treasury shares fell by 0.0229% to 135.94 million. Treasury shares increased from 246,000 to 277,200, while total issued shares remained unchanged at 136.22 million because the repurchased shares are being held in treasury and have not been cancelled.\nThe buy-back was made under the general mandate approved on 12 February 2026, which authorises the company to repurchase up to 13.62 million shares. Including this transaction, cumulative repurchases under the mandate amount to 277,200 shares, equivalent to 0.2035% of the issued share base on the mandate date. Under Listing Rule 10.06, the company is restricted from issuing new shares or disposing of treasury shares until 22 May 2026.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.0","shortVersion":"4.42.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1176038362","isCrawlerRequest":true}